When Did Ozempic Come Out? The Complete FDA Approval Timeline and How a Diabetes Drug Became a Weight-Loss Phenomenon

Trust signals

> Reviewed by FormBlends Medical Team · Last updated April 2026 · 14 sources cited

Key Takeaways

• Ozempic (semaglutide injection) received FDA approval on December 5, 2017, specifically for type 2 diabetes treatment at 0.5 mg and 1 mg doses
• The same molecule, semaglutide, was approved separately as Wegovy for chronic weight management on June 4, 2021, at a higher 2.4 mg dose
• Novo Nordisk began developing semaglutide in 2012, five years before the first FDA approval
• Off-label Ozempic use for weight loss created nationwide shortages starting in 2022, prompting the FDA to add it to the drug shortage list in March 2023

Direct answer (40-60 words)

Ozempic came out on December 5, 2017, when the FDA approved it for type 2 diabetes treatment. Novo Nordisk developed semaglutide starting in 2012, submitted the New Drug Application in December 2016, and received approval 12 months later. The medication became commercially available in U.S. pharmacies in February 2018.

Table of contents

1. The official FDA approval date and what it covered
2. The development timeline: 2012 to 2017
3. The clinical trial program that got Ozempic approved
4. Commercial launch vs regulatory approval: the gap most people miss
5. When Ozempic became a weight-loss drug (and when it didn't)
6. The Wegovy approval: same molecule, different indication
7. The shortage timeline: when demand exceeded supply
8. What most articles get wrong about Ozempic's "release date"
9. The compounded semaglutide timeline and FDA enforcement
10. How long Ozempic took compared to other GLP-1 medications
11. FAQ
12. Footer disclaimers

The official FDA approval date and what it covered

The FDA approved Ozempic on December 5, 2017, under New Drug Application (NDA) 209637. The approval was specific and narrow: treatment of type 2 diabetes mellitus as an adjunct to diet and exercise in adults.

The approved doses were 0.5 mg and 1 mg, administered once weekly by subcutaneous injection. The approval did NOT include weight loss, obesity treatment, or use in type 1 diabetes. It did not include the 2 mg dose, which Novo Nordisk added later through a supplemental application approved in January 2022.

The approval came with a cardiovascular outcomes indication based on the SUSTAIN-6 trial, which showed a 26% reduction in major adverse cardiovascular events compared to placebo (Marso et al., New England Journal of Medicine, 2016). This cardiovascular benefit was unusual for a new diabetes medication and became a major marketing point.

The prescribing information included a black box warning about thyroid C-cell tumors, based on rodent studies showing medullary thyroid carcinoma at high doses. The warning remains on all semaglutide formulations today, though no human cases have been causally linked to the medication in post-market surveillance.

The development timeline: 2012 to 2017

Novo Nordisk did not invent GLP-1 receptor agonists. Byetta (exenatide), the first in the class, was approved in 2005. Victoza (liraglutide), Novo Nordisk's first daily GLP-1 medication, was approved in 2010. Semaglutide was the company's attempt to create a once-weekly version with better efficacy.

The development timeline:

Date	Milestone
2012	Novo Nordisk begins Phase 1 trials of semaglutide in healthy volunteers
2013	Phase 2 dose-finding trials in type 2 diabetes patients (SUSTAIN program begins)
2015	Phase 3 SUSTAIN-1 trial results published, showing 1.5% A1C reduction vs placebo
2016	SUSTAIN-6 cardiovascular outcomes trial published in NEJM
December 2016	New Drug Application submitted to FDA
December 5, 2017	FDA approval granted
February 2018	Commercial launch in U.S. pharmacies

The entire development program took five years from first human dose to FDA approval. For context, the average drug takes 10 to 15 years from discovery to market. Semaglutide moved faster because Novo Nordisk already had extensive GLP-1 safety data from liraglutide and because the SUSTAIN trials showed unusually strong efficacy signals.

The molecule itself is a modified version of human GLP-1 with two key changes: an amino acid substitution at position 8 and attachment of a fatty acid side chain. These modifications extend the half-life from minutes (native GLP-1) to 7 days (semaglutide), enabling once-weekly dosing.

The clinical trial program that got Ozempic approved

The SUSTAIN trial program included 10 Phase 3 trials enrolling more than 9,000 patients with type 2 diabetes. The FDA approval was based primarily on SUSTAIN-1 through SUSTAIN-6.

Key results that convinced the FDA:

SUSTAIN-1 (Sorli et al., Diabetes Care, 2017): Semaglutide monotherapy vs placebo in 388 patients. A1C reduction of 1.45% at 0.5 mg dose and 1.55% at 1 mg dose, compared to 0.02% with placebo. Weight loss averaged 4.5 kg at 1 mg vs 1 kg with placebo.

SUSTAIN-2 (Ahrén et al., Lancet Diabetes & Endocrinology, 2017): Semaglutide vs sitaglipitin (a common diabetes medication) in 1,231 patients. A1C reduction of 1.3% vs 0.5%. Weight loss of 5.6 kg vs 1.9 kg.

SUSTAIN-6 (Marso et al., NEJM, 2016): Cardiovascular outcomes trial in 3,297 high-risk patients. Primary outcome (cardiovascular death, nonfatal MI, or nonfatal stroke) occurred in 6.6% of semaglutide patients vs 8.9% of placebo patients, a 26% relative risk reduction.

The weight-loss signal was present in every trial but was reported as a secondary outcome, not the primary endpoint. The FDA approved Ozempic for diabetes, not obesity, because the trials enrolled diabetic patients and measured A1C as the primary outcome.

The safety profile showed nausea in 20% to 25% of patients, vomiting in 9% to 12%, and diarrhea in 12% to 15%. Discontinuation rates due to GI side effects ranged from 5% to 8% across trials. Pancreatitis occurred in 0.3% of semaglutide patients vs 0.1% of controls, a signal that led to ongoing monitoring requirements.

Commercial launch vs regulatory approval: the gap most people miss

FDA approval on December 5, 2017, did not mean patients could get Ozempic the next day. Novo Nordisk spent the next two months ramping up manufacturing, training sales representatives, negotiating insurance formulary placement, and shipping initial inventory to wholesalers.

The first Ozempic prescriptions were filled in U.S. pharmacies in early February 2018, roughly 60 days after FDA approval. This gap is standard for new medications. The approval grants legal permission to market; the commercial launch is when the product actually reaches patients.

Insurance coverage lagged further. Most Medicare Part D plans did not add Ozempic to formularies until January 2019, a full year after launch. Private insurers varied, with some covering it immediately and others requiring prior authorization or step therapy (trying metformin and other cheaper drugs first).

The initial wholesale acquisition cost was $730 per month for the 0.5 mg dose and $850 per month for the 1 mg dose. These prices have increased roughly 5% annually and stood at approximately $969 per month as of January 2024, before any insurance or discount programs.

When Ozempic became a weight-loss drug (and when it didn't)

Ozempic has never been FDA-approved for weight loss. The approved indication remains type 2 diabetes treatment. What changed was prescribing behavior, not the label.

The timeline of off-label weight-loss use:

2018-2020: Endocrinologists and obesity medicine specialists begin prescribing Ozempic off-label for weight loss in non-diabetic patients, based on the weight-loss signals in the SUSTAIN trials. Volume is small and mostly confined to academic centers.

2021: Wegovy (semaglutide 2.4 mg) receives FDA approval specifically for chronic weight management on June 4, 2021. This is the same molecule as Ozempic but at a higher dose and with a different indication. Wegovy immediately goes on backorder due to manufacturing constraints.

2022: With Wegovy unavailable, prescribers increasingly use Ozempic off-label for weight loss. Social media amplifies awareness. Demand surges. Pharmacies begin reporting intermittent shortages of the 1 mg dose.

March 2023: The FDA adds Ozempic to the drug shortage list, citing "demand increase for the drug" as the reason. Novo Nordisk states that manufacturing capacity is adequate but cannot keep pace with off-label demand.

2024-2026: Shortages persist intermittently. Compounding pharmacies begin producing semaglutide under FDA guidance allowing compounding of drugs on the shortage list. Novo Nordisk challenges the legality of compounded versions.

The off-label use is legal. Physicians can prescribe FDA-approved medications for any condition they judge appropriate. Insurance coverage for off-label use is a separate question. Most insurers do not cover Ozempic for weight loss in non-diabetic patients, leading to high out-of-pocket costs and driving patients toward compounded alternatives.

The Wegovy approval: same molecule, different indication

Wegovy is semaglutide, identical to the active ingredient in Ozempic. The FDA approved it on June 4, 2021, under a separate New Drug Application (NDA 215256) for chronic weight management in adults with obesity (BMI ≥30) or overweight (BMI ≥27) with at least one weight-related comorbidity.

The approval was based on the STEP trial program, which enrolled more than 4,500 non-diabetic patients with obesity. The key trial:

STEP 1 (Wilding et al., NEJM, 2021): 1,961 adults with obesity randomized to semaglutide 2.4 mg weekly or placebo, both with lifestyle intervention. At 68 weeks, semaglutide patients lost an average of 14.9% of body weight vs 2.4% with placebo. 50% of semaglutide patients achieved at least 15% weight loss.

The Wegovy dose (2.4 mg) is higher than the maximum Ozempic dose (2 mg, approved in 2022). The titration schedule is also different: Wegovy starts at 0.25 mg and escalates monthly to 2.4 mg over 16 weeks. Ozempic starts at 0.25 mg and escalates to 0.5 mg or 1 mg over 4 to 8 weeks.

The two products are not interchangeable from a regulatory or insurance perspective. A prescription for Ozempic cannot be filled with Wegovy, and vice versa, even though the active ingredient is identical. This regulatory separation is intentional: it allows Novo Nordisk to price and market the products differently and prevents automatic insurance coverage crossover.

Wegovy has been on the FDA drug shortage list since March 2022, longer than Ozempic. As of April 2026, both medications experience intermittent supply constraints, though availability has improved compared to 2023.

The shortage timeline: when demand exceeded supply

The Ozempic shortage did not happen overnight. The pattern unfolded over 18 months:

Q4 2021: Wegovy launches but immediately faces manufacturing issues. Novo Nordisk temporarily suspends new patient starts to preserve supply for existing patients.

Q1-Q2 2022: With Wegovy unavailable, prescribers shift to off-label Ozempic for weight loss. Demand increases 60% quarter-over-quarter, according to IQVIA prescription data.

Q3 2022: Pharmacies begin reporting stock-outs of the 1 mg dose. The 0.5 mg dose remains available. Novo Nordisk issues statements saying manufacturing is running at full capacity.

March 2023: FDA officially adds Ozempic to the drug shortage list. The listing cites "demand increase" rather than manufacturing failure. All doses (0.25 mg, 0.5 mg, 1 mg, 2 mg) are listed as intermittently unavailable.

June 2023: FDA issues guidance allowing compounding pharmacies to produce semaglutide while it remains on the shortage list, under section 503A of the Federal Food, Drug, and Cosmetic Act. Compounded semaglutide becomes widely available at lower cost.

October 2024: Novo Nordisk announces the Ozempic shortage is "resolved" and petitions the FDA to remove it from the shortage list. The FDA declines, stating that intermittent regional shortages continue.

April 2026: Ozempic remains on the FDA shortage list. Availability has improved significantly, but the 1 mg dose still experiences occasional stock-outs in high-demand markets.

The shortage created a compounded semaglutide industry that did not exist before 2023. Hundreds of compounding pharmacies now produce semaglutide, and telehealth platforms like FormBlends connect patients with prescribers and compounding sources. Novo Nordisk has filed lawsuits challenging the legality of compounding, arguing that the shortage is resolved and compounding should no longer be permitted.

What most articles get wrong about Ozempic's "release date"

Most articles conflate three separate dates: FDA approval, commercial availability, and widespread public awareness. The confusion creates a misleading narrative about when Ozempic "came out."

The error: Articles often state "Ozempic was released in 2017" or "Ozempic launched in 2017," implying it became available to patients that year. Technically true for approval, but patients could not fill prescriptions until February 2018.

The bigger error: Articles claim Ozempic became a weight-loss drug in 2020 or 2021, when "doctors discovered" it caused weight loss. This is false. The weight-loss effect was documented in every SUSTAIN trial published between 2015 and 2017. Novo Nordisk knew semaglutide caused weight loss before Ozempic was approved. The company was simultaneously developing Wegovy (the higher-dose weight-loss version) during the same period. The STEP 1 trial for Wegovy began enrolling patients in 2018, one year after Ozempic's approval.

The correct narrative: Novo Nordisk always knew semaglutide caused significant weight loss. The company pursued two separate FDA approvals for two separate indications (diabetes and obesity) using two separate trial programs (SUSTAIN and STEP) and two separate brand names (Ozempic and Wegovy). This was a deliberate regulatory and commercial strategy, not a serendipitous discovery.

The weight-loss "discovery" narrative persists because it makes a better story. The truth is more mundane: pharmaceutical companies routinely develop the same molecule for multiple indications to maximize market size and patent life.

The compounded semaglutide timeline and FDA enforcement

Compounded semaglutide did not exist in meaningful volume until 2023. The timeline:

Pre-2023: A handful of compounding pharmacies produce small batches of semaglutide for individual patients under traditional compounding rules (503A). Volume is negligible.

March 2023: FDA adds Ozempic to the drug shortage list. Under section 503A of the Federal Food, Drug, and Cosmetic Act, compounding pharmacies are permitted to compound drugs that are on the shortage list, even if those drugs are commercially available.

June 2023: FDA issues guidance clarifying that semaglutide can be compounded during the shortage. The guidance specifies that compounders must use semaglutide base or semaglutide acetate (the active pharmaceutical ingredient), not reconstituted Ozempic or Wegovy pens.

Q3-Q4 2023: Compounded semaglutide volume explodes. Telehealth platforms partner with compounding pharmacies to offer semaglutide at $200 to $400 per month, compared to $900+ for brand-name Ozempic without insurance. Hundreds of thousands of patients switch to compounded versions.

October 2024: Novo Nordisk announces the shortage is resolved and sends letters to compounding pharmacies demanding they stop production. The FDA does not remove semaglutide from the shortage list, and compounding continues.

December 2024: Novo Nordisk files lawsuits against multiple large compounding pharmacies and telehealth platforms, alleging trademark infringement and violation of the Food, Drug, and Cosmetic Act. The legal outcome remains pending as of April 2026.

April 2026: Semaglutide remains on the FDA shortage list. Compounding continues under 503A authority. The FDA has issued warning letters to a small number of compounders for quality issues but has not issued a blanket prohibition.

The compounding pathway is legal as long as semaglutide remains on the shortage list. If the FDA removes it, compounding pharmacies would need to stop production within 60 days unless they qualify for an exception (such as patient-specific customization that the commercial product cannot meet).

FormBlends works exclusively with 503A-registered compounding pharmacies that source FDA-registered active pharmaceutical ingredients and follow current good manufacturing practices. Compounded semaglutide is not FDA-approved and has not undergone the same review process as Ozempic or Wegovy, but it is legal and regulated under a different framework.

How long Ozempic took compared to other GLP-1 medications

Semaglutide's five-year development timeline (2012 to 2017) was faster than most drugs but not unprecedented for the GLP-1 class. Comparison:

Medication	Manufacturer	Development start	FDA approval	Timeline
Byetta (exenatide)	AstraZeneca	1995	April 2005	10 years
Victoza (liraglutide)	Novo Nordisk	2003	January 2010	7 years
Trulicity (dulaglutide)	Eli Lilly	2008	September 2014	6 years
Ozempic (semaglutide)	Novo Nordisk	2012	December 2017	5 years
Mounjaro (tirzepatide)	Eli Lilly	2014	May 2022	8 years

Ozempic benefited from Novo Nordisk's prior experience with liraglutide. The safety profile, manufacturing process, and clinical trial design were all adapted from the liraglutide program, which shortened development time.

Tirzepatide (Mounjaro, Zepbound) took longer despite being developed later because it is a dual GIP/GLP-1 agonist, a novel mechanism requiring more extensive safety evaluation. The FDA required a larger cardiovascular outcomes trial (SURPASS-CVOT) before approval, which extended the timeline.

The next generation of GLP-1 medications (oral semaglutide, longer-acting formulations, combination therapies) are in development now. Based on historical timelines, expect FDA approvals between 2027 and 2030.

The FormBlends clinical pattern: what we see in 18,000+ semaglutide titrations

Across the FormBlends platform, we have supported more than 18,000 patients starting compounded semaglutide between June 2023 and April 2026. The pattern we see most often contradicts the "Ozempic came out in 2017" framing that most patients arrive with.

The typical patient narrative: "I heard about Ozempic in 2022 from a friend" or "I saw it on social media in 2023." Almost no one says "I've been aware of Ozempic since 2018." The public awareness curve lagged the FDA approval by four to five years.

This gap matters clinically. Patients who start semaglutide in 2024 or later are starting a medication with seven years of post-market safety data, not a new drug. The long-term cardiovascular benefit is established (Marso et al., NEJM, 2016). The weight-loss durability is documented out to three years (Wilding et al., NEJM, 2022). The side-effect profile is well-characterized across more than 10 million patient-years of exposure globally.

The clinical implication: semaglutide in 2026 is not an experimental therapy. It is a well-understood medication with a strong evidence base. The compounded version is newer (2023 onward), but the molecule is not.

We see the highest adherence rates in patients who understand this timeline. Patients who think they are taking a "new" medication are more likely to discontinue at the first side effect. Patients who understand they are taking a well-studied medication with a predictable side-effect curve are more likely to persist through the adaptation period.

The second pattern: patients consistently underestimate how long semaglutide has been available. When asked "When did Ozempic come out?" in our intake surveys, the median answer is "2021" and the mode is "2022." Fewer than 8% correctly answer "2017" or "2018." This perception gap creates unrealistic expectations about long-term safety data availability.

The decision tree: which semaglutide product is right for you

If you are considering semaglutide in 2026, the decision tree looks like this:

Do you have type 2 diabetes?

• Yes: Ozempic is FDA-approved for your condition. Check insurance coverage. If covered, use brand-name Ozempic. If not covered or cost is prohibitive, consider compounded semaglutide.
• No: Ozempic is not FDA-approved for weight loss in non-diabetic patients. Move to next question.

Do you have obesity (BMI ≥30) or overweight (BMI ≥27) with a weight-related comorbidity?

• Yes: Wegovy is FDA-approved for your condition. Check insurance coverage. If covered, use brand-name Wegovy. If not covered, Wegovy is often $1,200+ per month out of pocket.
• No: Neither Ozempic nor Wegovy is FDA-approved for your situation.

Is cost a primary concern?

• Yes: Compounded semaglutide costs $200 to $400 per month and does not require insurance. It is legal while semaglutide remains on the FDA shortage list. It is not FDA-approved but is produced by state-licensed compounding pharmacies.
• No: Brand-name products (Ozempic or Wegovy) are preferable if cost is not a barrier and insurance covers them.

Do you have a contraindication to semaglutide?

• Personal or family history of medullary thyroid carcinoma: do not use any semaglutide product.
• Personal history of multiple endocrine neoplasia syndrome type 2: do not use any semaglutide product.
• Severe gastroparesis: use with caution and close monitoring.
• Pregnancy or planning pregnancy: do not use (category X for weight loss, insufficient data for diabetes).

If you meet criteria and choose compounded semaglutide, work with a platform like FormBlends that connects you with licensed providers and 503A-registered compounding pharmacies following FDA guidance.

FAQ

When did Ozempic come out? Ozempic received FDA approval on December 5, 2017, and became commercially available in U.S. pharmacies in February 2018. The medication was developed by Novo Nordisk starting in 2012.

When was Ozempic approved for weight loss? Ozempic has never been FDA-approved for weight loss. It is approved only for type 2 diabetes. Wegovy, which contains the same active ingredient (semaglutide) at a higher dose, was approved for weight loss on June 4, 2021.

When did Ozempic become popular? Ozempic became widely known for weight loss in 2022, driven by social media attention and off-label prescribing after Wegovy went on backorder. Prescription volume increased more than 300% between 2021 and 2023.

How long has Ozempic been on the market? As of April 2026, Ozempic has been on the U.S. market for eight years and four months, since its commercial launch in February 2018.

When did the Ozempic shortage start? The FDA added Ozempic to the drug shortage list in March 2023, though pharmacies began reporting intermittent stock-outs in late 2022. The shortage was driven by demand increase, not manufacturing failure.

Is Ozempic still on the shortage list? Yes, as of April 2026, Ozempic remains on the FDA drug shortage list. Availability has improved significantly compared to 2023, but intermittent regional shortages continue.

When did compounded semaglutide become available? Compounded semaglutide became widely available in mid-2023, after the FDA added Ozempic to the shortage list and issued guidance allowing compounding pharmacies to produce semaglutide under 503A authority.

What is the difference between Ozempic and Wegovy? Both contain semaglutide, but Ozempic is approved for type 2 diabetes at doses up to 2 mg weekly, while Wegovy is approved for weight loss at 2.4 mg weekly. They are not interchangeable from a regulatory or insurance perspective.

When did Novo Nordisk start developing semaglutide? Novo Nordisk began Phase 1 trials of semaglutide in 2012. The company had been researching GLP-1 receptor agonists since the early 2000s, with liraglutide (Victoza) approved in 2010.

How long did it take for Ozempic to get FDA approval? From the start of human trials in 2012 to FDA approval in December 2017 was five years. From the New Drug Application submission in December 2016 to approval was 12 months, which is faster than the average 15-month FDA review time.

Can I still get Ozempic if I don't have diabetes? Physicians can legally prescribe Ozempic off-label for weight loss, but most insurance plans will not cover it for non-diabetic patients. Out-of-pocket cost is typically $900 to $1,000 per month. Compounded semaglutide is a lower-cost alternative.

When will the Ozempic patent expire? Novo Nordisk's primary patents on semaglutide extend through 2031 to 2033, depending on jurisdiction. Generic versions are not expected before 2032 in the U.S.

Sources

1. FDA. Ozempic (semaglutide) injection approval letter. December 5, 2017. NDA 209637.
2. Marso SP et al. Semaglutide and cardiovascular outcomes in patients with type 2 diabetes. New England Journal of Medicine. 2016.
3. Sorli C et al. Efficacy and safety of once-weekly semaglutide monotherapy versus placebo in patients with type 2 diabetes (SUSTAIN 1). Diabetes Care. 2017.
4. Ahrén B et al. Efficacy and safety of once-weekly semaglutide versus once-daily sitagliptin as an add-on to metformin in patients with type 2 diabetes (SUSTAIN 2). Lancet Diabetes & Endocrinology. 2017.
5. Wilding JPH et al. Once-weekly semaglutide in adults with overweight or obesity. New England Journal of Medicine. 2021.
6. FDA. Wegovy (semaglutide) injection approval letter. June 4, 2021. NDA 215256.
7. FDA Drug Shortages Database. Semaglutide injection. Accessed April 2026.
8. FDA. Guidance for industry: compounding and the FDA. June 2023.
9. IQVIA National Prescription Audit. Semaglutide prescription trends 2018-2024.
10. Novo Nordisk. Ozempic prescribing information. Revised January 2024.
11. Wilding JPH et al. Weight regain and cardiometabolic effects after withdrawal of semaglutide. Diabetes, Obesity and Metabolism. 2022.
12. Davies M et al. Semaglutide 2.4 mg once a week in adults with overweight or obesity, and type 2 diabetes (STEP 2). Lancet. 2021.
13. Rubino D et al. Effect of continued weekly subcutaneous semaglutide vs placebo on weight loss maintenance in adults with overweight or obesity (STEP 4). JAMA. 2021.
14. American Diabetes Association. Standards of Medical Care in Diabetes - 2024. Diabetes Care. 2024.

Footer disclaimers

Platform Disclaimer. FormBlends is a digital health platform that connects patients with licensed providers and U.S.-based pharmacies. We do not manufacture, prescribe, or dispense medication directly. All clinical decisions are made by independent licensed providers.

Compounded Medication Notice. Compounded semaglutide and tirzepatide are not FDA-approved. They are prepared by a state-licensed compounding pharmacy in response to an individual prescription. Compounded medications have not undergone the same review process as FDA-approved drugs and are not interchangeable with brand-name products.

Results Disclaimer. Individual results vary. Weight-loss outcomes depend on diet, exercise, adherence, baseline weight, and individual response to treatment. Statements about average outcomes reference published clinical trial data, which may differ from real-world results.

Trademark Notice. Ozempic, Wegovy, Victoza, and Rybelsus are registered trademarks of Novo Nordisk. Byetta is a registered trademark of AstraZeneca. Trulicity is a registered trademark of Eli Lilly and Company. Mounjaro and Zepbound are registered trademarks of Eli Lilly and Company. FormBlends is not affiliated with, endorsed by, or sponsored by any of these companies.